CN105535513A - Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823 - Google Patents

Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823 Download PDF

Info

Publication number
CN105535513A
CN105535513A CN201610088726.4A CN201610088726A CN105535513A CN 105535513 A CN105535513 A CN 105535513A CN 201610088726 A CN201610088726 A CN 201610088726A CN 105535513 A CN105535513 A CN 105535513A
Authority
CN
China
Prior art keywords
green
cough
rhizoma
preparation
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610088726.4A
Other languages
Chinese (zh)
Inventor
王梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xinshidai Medicine Science and Technology Co Ltd
Original Assignee
Jinan Xinshidai Medicine Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xinshidai Medicine Science and Technology Co Ltd filed Critical Jinan Xinshidai Medicine Science and Technology Co Ltd
Priority to CN201610088726.4A priority Critical patent/CN105535513A/en
Publication of CN105535513A publication Critical patent/CN105535513A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of traditional Chinese medicine and particularly relates to application of cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823 and a preparing method for the cough asthma tablets. The cough asthma tablets are prepared from 200 g of ll-grass of creeping bulbophyllum, 200 g of paederia scandens, 100 g of mahonia fortuneiFedde, 100 g of marsdenia tenacissima, 100 g of rhizoma bletillae, 100 g of polygonum cuspidatum, 100 g of speranskia tuberculata andd 100 g of rhizoma polygonati by the adoption of supercritical extraction. The rheum emodin content is increased greatly.

Description

Green and cough with asthma sheet suppresses the application in gastric adenocarcinoma cells BGC-823 cell proliferation in preparation
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of green and cough with asthma sheet and suppress application in gastric adenocarcinoma cells BGC-823 cell proliferation and preparation method that is green and cough with asthma sheet in preparation.
Background technology
Green and cough with asthma particulate level WS-10616(ZD-0616)-2002, be recorded in national standard for traditional Chinese medicines compilation internal medicine lung system (two) fascicle.Be made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, there is effect of nourishing YIN and moistening the lung, heat-clearing and toxic substances removing, removing stasis to stop bleeding, for the cough that the dry criminal's lung of heat causes, hectic fever, the diseases such as night sweat.
Summary of the invention
Goal of the invention: the object of the present invention is to provide a kind of green and application of cough with asthma sheet in preparation suppression gastric adenocarcinoma cells BGC-823 cell proliferation.
Another object of the present invention is to provide a kind of preparation method of green and cough with asthma sheet.
The object of the invention is by following scheme realize:
Green and cough with asthma sheet suppresses the application in gastric adenocarcinoma cells BGC-823 cell proliferation in preparation, described green and cough with asthma sheet is made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, described preparation method that is green and cough with asthma sheet comprises the steps: to get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO 2flow l-3ml/g crude drug min, extraction time 700-800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
Preferably, above-mentioned green and cough with asthma sheet suppresses the application in gastric adenocarcinoma cells BGC-823 cell proliferation in preparation, described preparation method that is green and cough with asthma sheet comprises the steps: to get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
In prior art, green and cough with asthma particulate oral, a 10g, 3-4 time on the one.Green and cough with asthma granule dosage is large.The heavy 0.50g of the every sheet of the green and cough with asthma sheet adopting the inventive method to be prepared into, only needs 2 at every turn, within 1st, takes 3-4 time.Dose is greatly reduced under the condition with more active component.This conclusion can be proved by following test.
The comparison of emodin content in green and cough with asthma sheet prepared by test one, distinct methods
Green and the cough with asthma sheet of l, instrument and reagent the present invention: by the preparation of embodiment 1 method, use 1000g crude drug, makes 200 through extracting, the heavy 0.50g of every sheet.Former green and cough with asthma granule, according to WS-10616(ZD-0616)-2002 standard method preparations.Agilent1200 high performance liquid chromatograph; METTLERAE240 electronic analytical balance; Emodin reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
Measure according to high performance liquid chromatography (Chinese Pharmacopoeia version in 2015 the 4th note on the use 15).
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Methanol-0.1% phosphoric acid solution (80: 20) is mobile phase; Determined wavelength is 437nm.Number of theoretical plate calculates should be not less than 4000 by emodin peak.
The preparation precision of reference substance solution takes emodin reference substance in right amount, adds methanol and makes the solution of every 1ml containing 10 μ g, to obtain final product.
Green and the cough with asthma sheet 10 of the present invention is got in the preparation of need testing solution, porphyrize, mixing, get 0.1g, accurately weighed, the 20ml that adds water makes dissolving, add hydrochloric acid 2ml, shake up, reflux 30 minutes, cooling, adds chloroform 30ml, supersound process 10 minutes, proceed in separatory funnel, divide and get chloroform solution, water liquid extracts 2 times with chloroform jolting again, each 15ml, combined chloroform liquid, evaporate to dryness in 80 DEG C of water-baths, residue dissolve with methanol is also transferred in 10ml measuring bottle, adds methanol dilution to scale, shake up, filter with microporous filter membrane (0.45 μm), get filtrate, to obtain final product.
The green of contrast and cough with asthma granule 20g are got in the preparation of reference product need testing solution, porphyrize, mixing, get 1g, accurately weighed, the 20ml that adds water makes dissolving, add hydrochloric acid 2ml, shake up, reflux 30 minutes, cooling, add chloroform 30ml, supersound process 10 minutes, proceed in separatory funnel, divide and get chloroform solution, water liquid extracts 2 times with chloroform jolting again, each 15ml, combined chloroform liquid, evaporate to dryness in 80 DEG C of water-baths, residue dissolve with methanol is also transferred in 10ml measuring bottle, add methanol dilution to scale, shake up, filter with microporous filter membrane (0.45 μm), get filtrate, obtain.
Algoscopy is accurate respectively draws reference substance solution and need testing solution, each 20 μ l of reference product need testing solution, injection liquid chromatography, measures, to obtain final product.
3, result
Result shows, in the green and cough with asthma sheet of the present invention, the content of emodin is 1.65-3.28mg/ sheet; And the content of emodin is 1.62mg/ bag (every bag containing granule 10g) in former green and cough with asthma granule, the emodin content each serving consumption 2 be the 2-4 of former granule 10g content doubly, when dose reduces, emodin content improves a lot.
Above-mentioned research shows, adopt green and cough with asthma sheet prepared by preparation method of the present invention, active constituent content is far away higher than WS-10616(ZD-0616) the green and cough with asthma granule prepared of method recorded of-2002 standards.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
After testing, in finished product, the content of emodin is 3.28mg/ sheet.
Embodiment 2
Get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 15MPa, temperature 30 DEG C, CO 2flow 1ml/g crude drug min, extraction time 900min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
After testing, in finished product, the content of emodin is 1.65mg/ sheet.
Embodiment 3
Get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 30MPa, temperature 60 C, CO 2flow 3ml/g crude drug min, extraction time 800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
After testing, in finished product, the content of emodin is 2.08mg/ sheet.
Embodiment 4: green and cough with asthma sheet suppresses the experimentation data of human gastric adenocarcinoma BGC-823 cell proliferation
1. experiment material
1.1 experiment cell strains
Human gastric adenocarcinoma BGC-823 cell, Shandong University's laboratory cell storehouse, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: the green and cough with asthma sheet of the present invention: prepare by embodiment 1 method.
Medicinal liquid liquid storage: take the green and cough with asthma sheet of 100mg, be dissolved in 5ml dehydrated alcohol, 0.2 μm of frit, 500 μ ldoff pipe subpackages ,-20 DEG C of storages, 0.2 μm of frit dehydrated alcohol is in order to the use of matched group simultaneously.
1.3 experiment reagent
DMEM (GIBCO company Cat.No.12100-061Lot.No.758137); Hyclone (Tian Hang bio tech ltd, Zhejiang Lot.No.100419); NaHC0 3(Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin(AMRESCO company); EDTA(AMRESCO company); PenicillinGSodiumSalt(AMRESCO company 1); StreptomycinSulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): PBS(laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (MD company of U.S. model: SPECTRAMAX190); C0 2incubator (FORMA model: 3111); Super-clean bench (safe and sound Inc. of Su Jing group moulding number: SW-CJ-ZFD); Pure water instrument (Sprlng company of U.S. model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (the accurate experimental facilities company in Shanghai model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μm of filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) BGC-823 cell DMEM+10%FBS is in 37 DEG C, 5%C0 2carry out cellar culture (10cm culture dish), when Growth of Cells is to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 DEG C of digestion 2min, add 5ml complete medium neutralization reaction wherein, proceeded in centrifuge tube after piping and druming cell, the centrifugal 5min of 1000rpm, adjustment concentration of cell suspension 3 × 10 4individual/ml.
2) enter in 96 well culture plates by cell kind, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 DEG C, 5%C0 2) cellar culture.
3) according to cell growth status, generally grow to 50%-70%, add green and cough with asthma sheet solution, continue to cultivate 24h.
4) add 20 μ lMTT solution (5mg/ml, i.e. 0.5%MTT) after 24h, continue to cultivate 4h.
5) after 4h, buckle method removes supernatant, pats dry gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, crystal is fully dissolved.The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide) simultaneously, often organizes the multiple hole of setting 6.
7) result represents with the suppression ratio of medicine to cell: cell proliferation suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value × 100%.Experiment repetition 3 times.
3. statistical disposition
Adopt the correlation analysis in MicrosoftExcel2007 software and Studentt inspection, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, compare with matched group, when dosage reaches 5mg/ml, to BGC-823 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has pole significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Green and the cough with asthma sheet of table 1 is to BGC-823 cell inhibitory effect influence research (X ± SD)
Group Drug level (mg/ml) Suppression ratio (%)
Matched group 0 0
1 5 7.15±2.98
2 10 14.29±3.69*
3 15 20.76±6.52**
4 20 26.55±9.87**
Note: compare with matched group, * P<0.01; * P<0.001.
5. experiment conclusion
Green and cough with asthma sheet of the present invention can suppress BGC-823 cell proliferation, and reduce the Growth of Cells number of BGC-823 cell, this effect is dose dependent.

Claims (2)

1. green and cough with asthma sheet suppresses the application in gastric adenocarcinoma cells BGC-823 cell proliferation in preparation, described green and cough with asthma sheet is made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, it is characterized in that, described preparation method that is green and cough with asthma sheet comprises the steps: to get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO 2flow l-3ml/g crude drug min, extraction time 700-800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
2. the green and cough with asthma sheet according to claim l suppresses the application in gastric adenocarcinoma cells BGC-823 cell proliferation in preparation, it is characterized in that, described preparation method that is green and cough with asthma sheet comprises the steps: to get little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 200, the heavy 0.50g of every sheet.
CN201610088726.4A 2016-02-17 2016-02-17 Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823 Withdrawn CN105535513A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610088726.4A CN105535513A (en) 2016-02-17 2016-02-17 Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610088726.4A CN105535513A (en) 2016-02-17 2016-02-17 Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823

Publications (1)

Publication Number Publication Date
CN105535513A true CN105535513A (en) 2016-05-04

Family

ID=55815415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610088726.4A Withdrawn CN105535513A (en) 2016-02-17 2016-02-17 Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823

Country Status (1)

Country Link
CN (1) CN105535513A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103494878A (en) * 2013-10-08 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of compound danshen tablets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103494878A (en) * 2013-10-08 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of compound danshen tablets

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
凌汶静: "常用抗肿瘤中药的临床应用与规律探", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 *
国家药品监督管理局: "《国家中成药标准汇编内科肺系（二）分册》", 1 December 2002 *

Similar Documents

Publication Publication Date Title
CN105535515A (en) Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of prostate cancer cells PC-3
CN105687726A (en) Application of Bulbophyllum calodictyon Schlecht.cough-asthma tablets to preparation of medicine for inhibiting proliferation of breast duct cancer cells T47D
CN105535513A (en) Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of gastric adenocarcinoma cells BGC-823
CN105343292A (en) Application of hance brandisia herb tablets in preparation of drugs for inhibiting endometrial carcinoma cell HEC-1B proliferation
CN105412333A (en) Application of hance brandisia herb tablets in preparation of medicine for inhibiting cell proliferation of glioma cells SHG-44
CN105535514A (en) Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of lung adenocarcinma cells H1299
CN105521298A (en) Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human oral epidermoid carcinoma cells KB
CN105521297A (en) Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human ileocecal carcinoma cells HCT-8
CN105663716A (en) Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of leukemia cells K562
CN105663718A (en) Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of glioma cells SHG-44
CN105663719A (en) Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of histocyte lymphoma cells U937
CN105521296A (en) Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human choriocarcinoma cells JAR
CN105616996A (en) Application of bulbophyllum and rhizoma bletillae cough and asthma tablets to preparing embryoma cell F9 proliferation suppressing medicines
CN105663717A (en) Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of kidney cancer cells ACHN
CN105663715A (en) Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251
CN105687727A (en) Application of Bulbophyllum calodictyon Schlecht.cough-asthma tablets to preparation of medicine for inhibiting proliferation of small intestine cancer cells HIC
CN105616995A (en) Application of bulbophyllum and rhizoma bletillae cough and asthma tablets to preparing uterine high-differentiation squamous cancer cell HCC (hepatic cellular cancer) proliferation suppressing medicines
CN105641446A (en) Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of human tongue cancer cells TCA 8113
CN105687728A (en) Application of antitussive and antiasthmatic tablets containing Bulbophyllum calodictyon to preparation of drugs for inhibiting SCaBER cell proliferation
CN105641448A (en) Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of cervical cancer cells U14
CN105641447A (en) Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of human bladder transitional cell carcinoma cells T-24
CN105412330A (en) Application of hance brandisia herb tablets in preparing medicine for inhibiting cell proliferation of breast medullary carcinoma cell Bcap-37
CN105456485A (en) Application of hance brandisia herb tablet in preparing drug for inhibiting mastocyte cancer cell P815 cell proliferation
CN105412332A (en) Application of hance brandisia herb tablets in preparation of medicine for inhibiting cell proliferation of epidermal carcinoma cells A-431
CN105456483A (en) Application of hance brandisia herb tablet in preparing drug for inhibiting UACC cell T47D cell proliferation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160504